These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28771049)

  • 1. Direct oral anticoagulants in the treatment of pulmonary embolism.
    Eldredge JB; Spyropoulos AC
    Curr Med Res Opin; 2018 Jan; 34(1):131-140. PubMed ID: 28771049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute pulmonary embolism: risk assessment, risk stratification and treatment options.
    Piovella F; Iosub DI
    Clin Respir J; 2016 Sep; 10(5):545-54. PubMed ID: 25619266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis, prognosis and therapeutic management of acute pulmonary embolism.
    Tapson VF
    Hosp Pract (1995); 2016 Aug; 44(3):164-72. PubMed ID: 27450108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants.
    Hull RD; Gersh MH
    Curr Med Res Opin; 2015 Feb; 31(2):197-210. PubMed ID: 25299352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for the treatment and prevention of thromboembolic disease.
    Antoniou S
    J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review.
    Toth PP
    Ann Med; 2014 Sep; 46(6):341-52. PubMed ID: 24888386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.
    Leung TS; Law EH
    Drug Des Devel Ther; 2015; 9():3557-69. PubMed ID: 26185422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
    Riva N; Ageno W
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
    Shirley M; Dhillon S
    Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.